| Title |
Targeting gastrointestinal stromal tumors: the role of regorafenib
|
|---|---|
| Published in |
OncoTargets and therapy, May 2016
|
| DOI | 10.2147/ott.s104081 |
| Pubmed ID | |
| Authors |
Brett Schroeder, Zula Li, Lee D Cranmer, Robin L Jones, Seth M Pollack |
| Abstract |
Gastrointestinal stromal tumor (GIST) is a devastating disease in the metastatic setting, but its natural history has been dramatically altered by the development of small molecule tyrosine kinase inhibitors, most notably imatinib. Although patients with advanced GIST live much longer today than they did in the past, imatinib-refractory disease remains a tremendous problem. For disease that is refractory to imatinib and sunitinib, regorafenib is an excellent option. In this review, we discuss the biology and clinical work establishing regorafenib as the standard of care for advanced GIST refractory to both imatinib and sunitinib. |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 2 | 15% |
| Student > Bachelor | 2 | 15% |
| Researcher | 2 | 15% |
| Student > Ph. D. Student | 2 | 15% |
| Other | 1 | 8% |
| Other | 2 | 15% |
| Unknown | 2 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 38% |
| Medicine and Dentistry | 2 | 15% |
| Agricultural and Biological Sciences | 2 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
| Nursing and Health Professions | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 2 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#5,363,866
of 25,461,852 outputs
Outputs from OncoTargets and therapy
#268
of 3,021 outputs
Outputs of similar age
#77,788
of 312,061 outputs
Outputs of similar age from OncoTargets and therapy
#14
of 123 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,021 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,061 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 123 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.